Xeris Biopharma Holdings, Inc. XERS Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s change in other liabilities?
- Xeris Biopharma Holdings, Inc. (XERS) reported change in other liabilities of -$4.68M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s change in other liabilities changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s change in other liabilities decreased by 445.1% year-over-year, from $1.36M to -$4.68M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s change in other liabilities?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s change in other liabilities has grown at a 35.4% compound annual growth rate (CAGR), from -$1.19M to $3.99M.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.